Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.47M | -19.29M | -21.12M | -21.33M | -25.43M |
| Total Depreciation and Amortization | 22.00K | 37.00K | 22.00K | 22.00K | 32.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.75M | 733.00K | 463.00K | 540.00K | 904.00K |
| Change in Net Operating Assets | 1.71M | -5.69M | -6.54M | -6.24M | -11.48M |
| Cash from Operations | -21.99M | -24.21M | -27.17M | -27.01M | -35.98M |
| Capital Expenditure | -- | -5.00K | -5.00K | -5.00K | -5.00K |
| Sale of Property, Plant, and Equipment | -- | 5.00K | 5.00K | 22.00K | 23.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 1.99M | 0.00 |
| Cash from Investing | -- | 0.00 | 0.00 | 2.01M | 18.00K |
| Total Debt Issued | 18.65M | 10.35M | 12.60M | 10.00M | 10.00M |
| Total Debt Repaid | -100.00K | -100.00K | -100.00K | -- | -- |
| Issuance of Common Stock | 829.00K | 7.48M | 7.49M | 12.42M | 23.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 156.00K | 156.00K | -21.00K | -21.00K |
| Cash from Financing | 19.38M | 17.88M | 20.14M | 22.40M | 33.41M |
| Foreign Exchange rate Adjustments | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.61M | -6.33M | -7.03M | -2.60M | -2.55M |